February 5, 2010 — Long-acting injectable olanzapine is effective in providing up to 24 weeks of maintenance treatment for patients with schizophrenia, according to results from a new randomized ...
Shares of Eli Lilly and Co. fell this morning after the company announced regulators had rejected its application for a long-acting, injectible version of its best-selling drug, Zyprexa. Lilly’s stock ...
Long-acting injection provides therapeutic olanzapine exposure for up to four weeks INDIANAPOLIS, Dec 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- The U.S. Food and Drug Administration ...
Oct. 2, 2003 — Olanzapine was associated with the fewest patients with extrapyramidal symptoms (EPS) at six months compared with baseline, according to the results of a large prospective trial ...
The Food and Drug Administration says it is investigating the unexplained deaths of two patients in the wake of receiving intramuscular injections of the antipsychotic medication Zyprexa (generic name ...
Janssen's Risperdal and Astrazeneca's Seroquel Overtake Eli Lilly's Zyprexa as the First-Line Antipsychotics of Choice in the Treatment for Schizophrenia Bristol Meyers Squibb/Otsuka Pharmaceutical's ...
For decades, a growing number of antipsychotic agents have been used for treating severe psychotic disorders. Conventional antipsychotic drugs, such as chlorpromazine and haloperidol, have ...
Atypical antipsychotic drugs are a mainstay of psychiatric pharmacotherapy and are used to treat a variety of psychiatric illnesses, most notably schizophrenia. These second generation drugs lack the ...
Olanzapine (Zyprexa) is approved to treat schizophrenia in adults and children ages 13 years and older, manic and mixed episodes related to bipolar I disorder in adults and children ages 13 years and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback